SCHEMBL3543014

SCHEMBL3543014

N#Cc1ncccc1-c1ccc(CC2CCN(C3CCCCC3)C2=O)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.44
F10 P00742 1/20 0.40
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
CYP11B2 P19099 1/20 0.37
PDE4A P27815 3/20 0.36
METAP2 P50579 2/20 0.36
ALDH1A1 P00352 1/20 0.36
P2RX7 Q99572 2/20 0.35
GRM2 Q14416 1/20 0.34
ROCK2 O75116 1/20 0.34
TNF P01375 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
BMPR1A P36894 1/20 0.33
ACVRL1 P37023 1/20 0.33
ACVR1 Q04771 1/20 0.33
CCR5 P51681 1/20 0.33
GRM5 P41594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998480 0.89 HSD11B1 (0.47) HSD11B1PDE4AMETAP2ALDH1A1P2RX7
SCHEMBL2992290 0.87 HSD11B1 (0.46) HSD11B1METAP2ALDH1A1P2RX7ROCK2
SCHEMBL3547892 0.85 HSD11B1 (0.52) HSD11B1PDE4AALDH1A1P2RX7ROCK2
SCHEMBL2992390 0.85 HSD11B1 (0.43) HSD11B1PDE4AMETAP2ALDH1A1ROCK2
SCHEMBL13241878 0.85 HSD11B1 (0.43) HSD11B1ALDH1A1P2RX7ROCK2BMPR1A
Hydrochloric Acid SCHEMBL3882886 0.85 HSD11B1 (0.51) HSD11B1PDE4AP2RX7ROCK2PDE4C
SCHEMBL5543772 0.82 HSD11B1 (0.51) HSD11B1P2RX7ROCK2PDE4DCCR5
SCHEMBL3550336 0.81 HSD11B1 (0.43) HSD11B1CYP11B2PDE4AROCK2TNF
SCHEMBL3001080 0.80 HSD11B1 (0.48) HSD11B1CYP11B2ROCK2PDE4DCCR5
SCHEMBL3549083 0.80 HSD11B1 (0.47) HSD11B1PDE4AP2RX7ROCK2PDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713979-B2 Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2010-05-11 US claimed
EP-1807072-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2009-01-07 EP claimed
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-11-06 US claimed
US-20100184764-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2010-07-22 US disclosed
US-7713979-B2 Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2010-05-11 US disclosed
EP-1807072-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2009-01-07 EP disclosed
EP-1807072-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2009-01-07 EP disclosed
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 HSD11B1, HSDL2, HSD17B1 HSD11B1 1/4885F10 629/4885PRMT5 2150/4885
US-20100184764-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885F10 2100/4885PRMT5 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.